HIV-1 viral decay in blood and semen in antiretroviral-naïve adults initiating dolutegravir/lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide

被引：0

作者：

Liu, Yongjian ^{[1
]}

Wang, Ran ^{[2
]}

Sun, Lijun ^{[2
]}

Li, Aixin ^{[2
]}

Li, Zhengyang ^{[1
]}

Kang, Qian ^{[1
]}

Feng, Yuxin ^{[1
]}

Lv, Shiyun ^{[2
]}

Zhai, Yuanyi ^{[2
]}

Li, Rui ^{[2
]}

Hua, Wei ^{[2
]}

Wang, Xi ^{[2
]}

Gao, Yue ^{[2
]}

Wang, Zhangli ^{[2
]}

Feng, Yuguang ^{[2
]}

Han, Jingwan ^{[1
]}

Jia, Lei ^{[1
]}

Wang, Xiaolin ^{[1
]}

Zhang, Bohan ^{[1
]}

Li, Hanping ^{[1
]}

Li, Jingyun ^{[1
]}

Zhang, Tong ^{[2
]}

Wu, Hao ^{[2
]}

Li, Lin ^{[1
]}

Dai, Lili ^{[2
]}

机构：

[1] Acad Mil Med Sci, State Key Lab Pathogen & Biosecur, 20 East St, Beijing, Peoples R China

[2] Capital Med Univ, Beijing Youan Hosp, 8 Xitoutiao, Beijing, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2025年 / 65卷 / 01期

基金：

北京市自然科学基金; 中国国家自然科学基金;

关键词：

Integrase strand-transfer inhibitor; Nucleoside reverse-transcriptase inhibitor; Seminal plasma; Viral reservoir; Sanctuary site; Inflammatory biomarker; ANTIRETROVIRAL THERAPY; PLUS LAMIVUDINE; SEMINAL PLASMA; RNA; PREVENTION; DYNAMICS; STRATEGY; DRUGS; MEN;

D O I：

10.1016/j.ijantimicag.2024.107396

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background Co-formulated dolutegravir and lamivudine (DTG/3TC) is recommended as the first-line antiretroviral therapy (ART); however, the data on the viral decay in seminal plasma (SP) and blood plasma (BP), as well as changes in inflammatory biomarkers in BP, remain limited among antiretroviral-na & iuml;ve people with HIV (PWH) receiving DTG/3TC. A prospective observational cohort study was conducted to compare the impact of DTG/3TC vs. bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) on viral decay kinetics and changes in inflammatory biomarkers in antiretroviral-na & iuml;ve PWH. Methods Newly diagnosed PWH who initiated BIC/FTC/TAF (n=57) or DTG/3TC (n=43) were enrolled. BP and SP were collected at 0, 4, 12, 24, and 48 weeks after ART initiation. The primary endpoint was viral suppression of HIV-1 in BP and SP at week 48. Secondary endpoints included changes in HIV-1 DNA levels and inflammatory biomarkers over the 48-week follow-up. Results Overall, 96 (96.0%) PWH completed the 48-week follow-up (DTG/3TC, n=40; BIC/FTC/TAF, n=56). Viral suppression rates in BP and SP were comparable in the BIC/FTC/TAF and DTG/3TC groups in the per-protocol analyses at week 48 (BP, 96.4% vs. 100%, P=0.519; SP, 100% vs. 100%, P>0.999). Both regimens demonstrated similar effectiveness in reducing HIV-1 RNA levels in BP (3.0 vs. 3.1 log(10) copies/mL) and SP (0.9 vs. 1.2 log(10) copies/mL). There were no statistically significant differences in the reductions in HIV-1 DNA levels and changes in inflammatory biomarkers over the 48-week follow-up. Conclusion These findings indicated comparable effectiveness of DTG/3TC vs. BIC/FTC/TAF in achieving viral suppression in BP and SP, and similar changes in inflammatory biomarkers in BP.

引用

页数：7

共 33 条

[1]

Acquired Immunodeficiency Syndrome and Hepatitis C Professional GroupSociety of Infectious Diseases Chinese Medical Association, 2024, Chin J Infect Dis, V42, pE01, DOI [10.3760/cma.j.cn311365-20240328-00081, DOI 10.3760/CMA.J.CN311365-20240328-00081]

[2]

[Anonymous], Guidelines for the use of antiretroviral agents in adults and adolescents with HIV

[3] CCL2: A potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis [J].

Ansari, Abdul W. ;

Heiken, Hans ;

Meyer-Olson, Dirk ;

Schmidt, Reinhold E. .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 41 (12) :3412-3418

[4] Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission [J].

Baeten, Jared M. ;

Kahle, Erin ;

Lingappa, Jairam R. ;

Coombs, Robert W. ;

Delany-Moretlwe, Sinead ;

Nakku-Joloba, Edith ;

Mugo, Nelly R. ;

Wald, Anna ;

Corey, Lawrence ;

Donnell, Deborah ;

Campbell, Mary S. ;

Mullins, James I. ;

Celum, Connie .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (77)

[5] Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials [J].

Cahn, Pedro ;

Sierra Madero, Juan ;

Ramon Arribas, Jose ;

Antinori, Andrea ;

Ortiz, Roberto ;

Clarke, Amanda E. ;

Hung, Chien-Ching ;

Rockstroh, Jurgen K. ;

Girard, Pierre-Marie ;

Sievers, Jorg ;

Man, Choy ;

Currie, Alexander ;

Underwood, Mark ;

Tenorio, Allan R. ;

Pappa, Keith ;

Wynne, Brian ;

Fettiplace, Anna ;

Gartland, Martin ;

Aboud, Michael ;

Smith, Kimberly .

LANCET, 2019, 393 (10167) :143-155

[6] Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir plus lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial) [J].

Charpentier, Charlotte ;

Peytavin, Gilles ;

Raffi, Francois ;

Burdet, Charles ;

Landman, Roland ;

Le, Minh P. ;

Katlama, Christine ;

Collin, Gilles ;

Benalycherif, Aida ;

Cabie, Andre ;

Mentre, France ;

Yazdanpanah, Yazdan ;

Descamps, Diane ;

Joly, Veronique .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (06) :1611-1617

[7] Effects of Urethritis on Human Immunodeficiency Virus (HIV) in Semen: Implications for HIV Prevention and Cure [J].

Chen, Jane S. ;

Matoga, Mitch ;

Massa, Cecilia ;

Tegha, Gerald ;

Ndalama, Beatrice ;

Bonongwe, Naomi ;

Mathiya, Esther ;

Jere, Edward ;

Banda, Gabriel ;

Loftis, Amy J. ;

Lancaster, Kathryn E. ;

Miller, William C. ;

Hoffman, Irving F. ;

Cohen, Myron S. .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) :E2000-E2004

[8] Antiretroviral Therapy for the Prevention of HIV-1 Transmission [J].

Cohen, M. S. ;

Chen, Y. Q. ;

McCauley, M. ;

Gamble, T. ;

Hosseinipour, M. C. ;

Kumarasamy, N. ;

Hakim, J. G. ;

Kumwenda, J. ;

Grinsztejn, B. ;

Pilotto, J. H. S. ;

Godbole, S. V. ;

Chariyalertsak, S. ;

Santos, B. R. ;

Mayer, K. H. ;

Hoffman, I. F. ;

Eshleman, S. H. ;

Piwowar-Manning, E. ;

Cottle, L. ;

Zhang, X. C. ;

Makhema, J. ;

Mills, L. A. ;

Panchia, R. ;

Faesen, S. ;

Eron, J. ;

Gallant, J. ;

Havlir, D. ;

Swindells, S. ;

Elharrar, V. ;

Burns, D. ;

Taha, T. E. ;

Nielsen-Saines, K. ;

Celentano, D. D. ;

Essex, M. ;

Hudelson, S. E. ;

Redd, A. D. ;

Fleming, T. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (09) :830-839

[9] Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE trial [J].

Cossarizza, Andrea ;

Cozzi-Lepri, Alessandro ;

Mattioli, Marco ;

Paolini, Annamaria ;

Neroni, Anita ;

De Biasi, Sara ;

Lo Tartaro, Domenico ;

Borella, Rebecca ;

Fidanza, Lucia ;

Gibellini, Lara ;

Beghetto, Barbara ;

Roncaglia, Enrica ;

Nardini, Giulia ;

Milic, Jovana ;

Menozzi, Marianna ;

Cuomo, Gianluca ;

Digaetano, Margherita ;

Orlando, Gabriella ;

Borghi, Vanni ;

Guaraldi, Giovanni ;

Mussini, Cristina .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[10] Durable Efficacy of Switching From a 3-or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196 [J].

De Wit, Stephane ;

Bonnet, Fabrice ;

Osiyemi, Olayemi ;

Bisshop, Fiona ;

Olalla, Julian ;

Routy, Jean-Pierre ;

Wyen, Christoph ;

Moodley, Riya ;

Pappa, Keith ;

Wang, Ruolan ;

Oyee, James ;

Saggu, Parminder ;

Letang, Emilio ;

Wynne, Brian ;

Jones, Bryn ;

Smith, Kimberly Y. ;

Ait-Khaled, Mounir .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (02) :156-160

← 1 2 3 4 →